Tonight, we're following breaking news out of the CDC where top officials are resigning in mass after sudden changes to COVID vaccine policies were announced earlier today. This afternoon, the FDA approved the COVID vaccine for the fall, but restricted who is eligible to receive it. In a reversal of long-standing policy, the FDA now says that the vaccine that has saved millions of lives in this country and around the world, is only recommended for adults 65 and older, plus kids and adults with underlying he ...

So any but the president yesterday actually did something that I think he should have been doing for a very long time and that is he was touting his administration's role in making a COVID uh vaccine despite the skepticism from his own base including you know RFK Jr.. and during yesterday's cabinet meeting he praised his administration's handling of the pandemic roll out of operation warp speed. Take a listen. I had the greatest uh economy in the history of our country. My first four years despite co which ...

As kids across the country head back to school, we are seeing a record number of parents exempting those kids from vaccines. Even with the highest number of measles cases in decades and a new co variant on the rise, HHS Secretary Robert F. Kennedy Jr.. has rolled back has rolled back co vaccine. But medical organizations like the American Academy of Pediatrics are standing firm on their recommendations for childhood vaccines. Joining us now, the president of the American Academy of Pediatrics, Dr.. Susan Cr ...

Joining me now is Dr. . Paul Offett. He is the director of the vaccine education center at Children's Hospital of Philadelphia.Welcome Dr. . Offett. >> Thank you.>> If we remember the timeline of the development of the COVID vaccine, we went into lockdown in March of 2020. I believe the first shot in arms of healthcare workers was December of that year if I wasn't mistaken. That's less than a year.A traditional vaccine takes four to five years of development. Why is it so much faster. The typical production ...

Tonight, current and former CDC employees and allies in Atlanta fired up, angry following Friday evening shooting that left a responding police officer and the alleged gunman dead. >> Secretary Kennedy likened CDC to a Nazi death camp. He has accused CDC workers of deliberately harming people.He has spread disinformation about the vaccine and told people that the vaccine causes harms that it does not does not cause. >> Dr. . Anna Yousef was on a call held by the CDC director yesterday with members of the AY ...

Regulatory Transparency & Flexibility - The FDA emphasizes regulatory flexibility, tailoring processes to specific conditions, especially rare and incurable ones, considering limited alternatives [1][2] - Drug developers and pharmaceutical companies deserve predictability, as highlighted by the framework for COVID vaccine regulation published in the New England Journal of Medicine [4][5] - The FDA aims for transparency by releasing decision letters to the public and drug developers, modernizing the agency, and addressing misinformation, including rewriting dietary guidelines with USDA [12][13] Vaccine & Booster Recommendations - While the CDC sets the vaccine schedule, the FDA has approved vaccines for high-risk populations; booster shots for low-risk individuals require more research [5][6] - There are scientific unknowns and polarizing views regarding the necessity and frequency of COVID boosters, especially for healthy young individuals, alongside concerns about vaccine injuries [8][9] Public Trust & Misinformation - Public trust in health institutions has significantly declined, with trust in doctors and hospitals dropping from 71% to 40% in the last four years, necessitating rebuilding efforts [10][11] - The FDA is addressing misinformation by rewriting the food pyramid with USDA, ending the "war on natural saturated fat," and clarifying the difference between whole grains and ultra-processed foods [13] Food & Dietary Guidelines - The FDA is taking action to remove petroleum-based food dyes, inspired by previous discussions on removing "poisons and chemicals" from the food supply [17][18] - The FDA acknowledges the addictive nature of processed foods, designed by food scientists, contributing to chronic diseases and insulin resistance in children [20][21] - The SNAP program now has waivers for states to restrict taxpayer dollars from being used for junk food and sugary drinks [22] Women's Health - Women's health issues have been historically overlooked, prompting the FDA to host a roundtable on hormone replacement therapy for perimenopausal women [25][26] - The NIH is refocusing its funding to study root causes of chronic diseases, including school lunch programs, sleep medicine, and environmental exposures [29] Opioid Crisis & Supplements - The FDA, along with the DEA, is taking action to schedule 7-hydroxy mitragynine (7-OHM), a synthetic opioid found in vape stores, which is 13 times more potent than morphine [35][36] - The FDA is concerned about the unregulated nature of supplements and the need for regulation to ensure Americans are taking trustworthy and healthy products [33]

The American Academy of Pediatrics is suing HHS Secretary RFK Jr. . saying, quote, "We believe the children deserve better." The lawsuit alleges changes to COVID vaccine recommendations without a scientific reason. And Kennedy's firing of vaccine advisors, replacing them with multiple vaccine skeptics, are illegal and are outside established scientific practice.Joining us now, the president of the American Academy of Pediatrics, Dr. . Susan Cresley. Uh, doctor, thank you so much for joining us.Um, please ex ...

Company Overview - Moderna is focused on building a diverse portfolio of products utilizing mRNA technology, targeting areas such as infectious diseases, cancer, rare diseases, and autoimmune diseases [3]. Strategic Priorities - The company has outlined three main priorities for the year: 1. To drive sales through approved products, specifically COVID-19 and RSV vaccines [3]. 2. To launch new products to diversify and grow the top line, with up to 10 launches planned over the next few years and several Biologics License Applications (BLAs) already filed [4]. 3. To resize the company from a cost perspective in response to the transition from pandemic-related sales [4].

Core Viewpoint - High dividend yields do not always indicate high risk; some stocks can be undervalued despite high yields [1][2] Group 1: Pfizer - Pfizer offers a dividend yield of 7.5% but has faced bearish sentiment due to declining revenue from its COVID vaccine and multiple patent expirations [4][5] - The stock has decreased over 35% in the past five years, raising concerns about future growth [4] - Despite uncertainties, Pfizer generated $11.2 billion in free cash flow over the last 12 months, with dividend payments totaling $9.6 billion, indicating a manageable dividend [5][6] - The stock trades at less than 8 times estimated future profits, providing a margin of safety for patient investors [6] Group 2: Verizon Communications - Verizon has a dividend yield of 6.2% but has seen a negative return of 21% over the past five years due to rising interest rates and economic concerns [8] - The company lost 289,000 wireless subscribers in Q1 2025, significantly worse than Wall Street's expectations [9] - Verizon's dividend payout ratio is 64% of its earnings, suggesting stability in its ability to maintain dividend payments despite recent performance [11] Group 3: Telus - Telus has the highest dividend yield on the list at 7.6% and has seen a modest decline of 3% over the past five years [12] - The company reported operating revenue of 5 billion Canadian dollars, reflecting a 3% year-over-year growth [12] - Telus generated CA$488 million in free cash flow, a 22% increase year-over-year, and has recently raised its dividend by 7% [13] - The company expects to continue increasing its dividend annually by 3% to 8% until the end of 2028, making it a stable long-term investment [13][14]

Financial Data and Key Metrics Changes - Q1 revenues were $100 million, with a net loss of $1 billion, reflecting the seasonal nature of the respiratory vaccine business [6][12] - Cash and investments at the end of the quarter totaled $8.4 billion, down from $9.5 billion at the end of Q4 [16] - R&D expenses decreased by 19% year over year to $856 million, driven by lower clinical development spending [14][19] - SG&A expenses were $212 million, down 23% year over year, reflecting broad-based cost reductions [15] Business Line Data and Key Metrics Changes - Net product sales were $86 million, primarily from COVID vaccine sales, with the U.S. accounting for about one-third of total sales [12][13] - Total revenue for the quarter was $108 million, a decrease of 35% year over year [13] - Cost of sales was $90 million, representing 104% of net product sales, up from 58% in the prior year [14] Market Data and Key Metrics Changes - Lower vaccination rates were observed compared to Q1 last year, indicating a transition of COVID into routine seasonal vaccination patterns [13] - The company expects total revenue in 2025 to be in the range of $1.5 billion to $2.5 billion, with first-half sales of approximately $200 million [17] Company Strategy and Development Direction - The company is focused on three priorities: expanding markets for commercial products, advancing its pipeline to drive sales growth, and executing with financial discipline [7][39] - The oncology portfolio is being expanded with the Checkpoint Medicine program, and the company aims to drive sales for approved products [8][39] - A commitment to achieve a breakeven target on a cash cost basis by 2028 has been established, with plans for significant cost reductions by 2027 [21][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing need for COVID vaccination, particularly in the upcoming fall season, despite the competitive market environment [52] - The company remains engaged with the FDA and anticipates continued productive exchanges regarding its product approvals [51] - The management is optimistic about the potential for new product approvals and the impact on sales growth [41][42] Other Important Information - The company plans to reduce annual GAAP expenses by over $6 billion from 2023 to 2027, representing a 55% reduction [22] - The Phase III FRU program has exceeded the required number of case accruals for an interim vaccine efficacy analysis [9] Q&A Session Summary Question: Comments on FDA interactions and potential risks to the vaccine business outlook - Management noted that interactions with the FDA have been productive and ongoing, with a focus on providing necessary data for product reviews [51][52] Question: Update on INT Phase III data expectations - Management believes that a 2026 readout for the Phase III melanoma study is still reasonable, pending event accruals [56][58] Question: Concerns about future market share changes in COVID revenue - Management indicated that script data shows a consistent market share of around 38%, and they are focused on managing working capital effectively [100][101] Question: Flu vaccine interim data expectations - Management did not provide specific guidance on total events for the flu vaccine analysis, stating that they will conduct the analysis once the season is over [105]